课题基金 / 基金详情

Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression

Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
尿毒症毒素介导 ApoA-I 表达下调的机制
批准号:
7673186
负责人:
Hamid Moradi
金额:
$6.1万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2010-06-30

项目摘要

项目成果

Hamid Moradi的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):在过去的几十年里,世界范围内慢性肾脏疾病(CKD)的患病率呈惊人的上升趋势。动脉粥样硬化性心血管疾病是CKD患者死亡的主要原因。HDL水平降低和HDL介导的逆向脂质转运缺陷是CKD人群动脉粥样硬化素质的主要因素。CKD患者血清HDL水平下降的一个主要原因是载脂蛋白A- 1的减少,载脂蛋白A- 1是HDL的主要结构和功能成分。我们实验室的动物实验表明,尿毒症大鼠血清中apoa - 1含量降低,肝脏中mRNA表达降低。此外,在尿毒症条件下,ApoA-l的表达、合成和分泌减少已被证实。鉴于大量证据表明ApoA-l缺乏与心血管事件和死亡率风险增加有关,旨在破译CKD ApoA-l缺乏机制的研究至关重要。我们假设CKD患者血清中存在的尿毒症毒素在转录水平上下调apoa - 1。利用apoa - 1启动子-荧光素酶结构,我们发现暴露于尿毒症的肝细胞中apoa - 1启动子活性降低。此外,我们认为这种抑制作用是通过apoa - 1启动子中的尿毒症反应元件(URE)介导的。因此,apoa - 1基因启动子中的一个或多个转录因子与URE结合会导致转录活性降低。此外,我们假设尿毒症对URE的影响发生在肝脏和肠细胞(这两种细胞类型负责产生血清apoa - 1)中。利用缺失映射和启动子荧光素酶报告结构,我们希望在apoa - 1启动子中确定一个URE。随后,位点定向诱变将用于识别URE中的顺式调控位点。此外,可能参与apoa - 1调控的转录因子将通过计算分析确定。最后,利用电泳迁移率转移和超转移测定,鉴定出的调节蛋白与ApoA-l启动子中的顺式调节元件的结合将得到证实。这些研究将在人类肝脏(HepG2)和肠道(Caco2)细胞中进行。流行病学观察表明,ApoA-l的减少与心血管死亡率的增加有关,同时CKD是ApoA-l缺乏的状态,这使得该分子成为一个有吸引力的治疗靶点。一旦确定了CKD中ApoA-l缺乏的机制,就可以设计出更有效的治疗方法,专门针对纠正这些有害的机制。
英文摘要
DESCRIPTION (provided by applicant): During the past few decades there has been an alarming rise in the prevalence of chronic kidney disease (CKD) worldwide. Atherosclerotic cardiovascular disease is the major source of mortality in CKD patients. Decreased HDL levels and defective HDL-mediated reverse lipid transport are major contributors to the atherogenic diathesis in the CKD population. A major cause of decreased serum HDL level in CKD is the reduction in apoliprotein A-l, the major structural and functional component of HDL. Animal studies in our lab have shown decreased ApoA-l in serum and decreased mRNA expression in liver of uremic rats. Furthermore, decreased ApoA-l expression, synthesis and secretion by human liver cells under uremic conditions has been documented. Given the preponderance of evidence linking ApoA-l deficiency to increased risks of cardiovascular events and mortality, studies aimed at deciphering the mechanisms responsible for the ApoA-l deficiency of CKD are of vital importance. We hypothesize that uremic toxins present in the serum of CKD patients are responsible for down regulation of ApoA-l at the transcriptional level. Using an ApoA-l promoter-luciferase construct, we have shown decreased ApoA-l promoter activity in liver cells exposed to uremia. Furthermore, we believe this inhibitory effect is mediated through a uremia responsive element (URE) within the ApoA-l promoter. Therefore, binding of one or more transcription factors to URE in the promoter of the ApoA-l gene results in decreased transcriptional activity. In addition, we hypothesize that the effect of uremia on the URE occurs in both the liver and intestinal cells (the two cell types responsible for producing serum ApoA-l). Using deletion mapping and a promoter luciferase reporter construct, we hope to identify a URE in the ApoA-l promoter. Subsequently, site-directed mutagenesis will be utilized to identify cis-regulatory sites within the URE. Furthermore, transcription factors potentially involved in ApoA-l regulation will be identified using computational analysis. Finally, using electrophoretic mobility shift and supershift assays, binding of the identified regulatory proteins to the cis-regulatory elements in the ApoA-l promoter will be confirmed. These studies will be carried out in human liver (HepG2) and intestinal (Caco2) cells. The epidemiological observation that decreased ApoA-l is associated with increased cardiovascular mortality along with the fact that CKD is a state of ApoA-l deficiency makes this molecule an attractive target for therapy. Once the mechanisms responsible for ApoA-l deficiency in CKD have been identified, then more effective therapies aimed specifically at correcting those deleterious mechanisms can be devised.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HDL function and mortality in end stage renal disease
  • 批准号:
    9237202
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2015
  • 负责人:
    Hamid Moradi
  • 依托单位:
HDL function and mortality in end stage renal disease
  • 批准号:
    10205993
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2015
  • 负责人:
    Hamid Moradi
  • 依托单位:
Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
Mechanisms involved in uremic toxin mediated down regulation of ApoA-I expression
海外基金